### **Partners**

PDA (Network of Polyclinics for Dialysis and Apheresis) promotes networking activities among medical professionals and institutions in the Rostock area particularly focusing on the management of renal, immunological and dyslipidemic conditions. Thereby, PDA improves communication between clinicians and researchers and helps to develop and implement special training programs for extracorporeal treatment.

ACR Apheresis Center Rostock is part of the PDA network. It is equipped with most advanced apheresis techniques >2,000 apheresis treaments are performed annually. The ACR is internationally respected and very well connected to other apheresis groups. It supports educational and scientific activities and personnel exchange programs.

**BioArtProducts GmbH B.A.P.** is the operating company for the German Lipid Apheresis Register and a medical research & service company that is an integrative part of a regional interdisciplinary outpatient clinic network. B.A.P. develops and helps to implement screening programs, treatment algorithms and quality management systems as well as proprietary software for medical studies and registers.

**PUM Department of Nephrology, Transplantation, Internal Medicine** Department of Nephrology, Transplantation and Internal Medicine, Pomeranian Medical University, Szczecin, Poland, Department of Nephrology, Transplantation and Internal Medicine, Pomeranian Medical University, Szczecin, Poland, Department of Nephrology, Transplantation and Internal Medicine, Pomeranian Medical University, Szczecin, Poland, Department of Nephrology, Transplantation and Internal Medicine, Pomeranian Medical University,

BCV (BioConValley) is a central point of contact and service provider for life sciences and healthcare industries, and co-founder of the international ScanBalt fmba network of biotechnology initiatives around the Baltic Sea. Within the Eco4life project BioCon Valley and PUM together with PDA, B.A.P. and ACR intend to congregate partners from the Baltic Sea Area for the setup of a Baltic Apheresis Working Group, within the framework of the ScanBalt Flagship project "Baltic Sea Health Region"

## **Registration Conference Workshop**

Please register until October 11th, 2013!

For the international conference please register separately. (separate flyer)

Via Fax: +49 3834 515102 Via E-Mail: bp@bcv.org

via L-Mail . Dp@bcv.org	
Name	
First Name	
Title	
Institution	
Address/Street	No
ZIP/City	
Phone	
Fax	
E-Mail	

Find more information on www.eco4life.info
The conference will be held in English. The participation in the event is free.

"Eco4Life- South Baltic Network for Environmental and Life Sciences to Boost Cross Border Cooperation" is part-financed by the EU-South Baltic Programme.

For German participants:

Die Veranstaltungen entsprechen den Kriterien der Fortbildungszertifizierung der Ärztekammer M-V






# **Eco4Life Conference Workshop**

BALTIC APHERESIS WORKING GROUP

### **APHERESIS**



**15th October 2013**Conference Workshop
Hotel Radisson, Szczecin









### **Information**

Organized by: Birgit Pscheidl

(Lead Partner Eco4Life, BioConValley)

www.eco4life.info

Dr. Wolfgang Ramlow

ACR/PDA, Rostock, Germany

Thomas Zimmermann B.A.P, Rostock, Germany

Location: Conference Workshops (October 15th)

Radisson Blu Hotel, Szczecin

**Conference Center** 

Plac Rodła 10, Szczecin, Poland

## **Topic**

The Eco4Life project partners BioConValley (BCV) and the Pomeranian Medical University together with PDA (Network of Polyclinics for Dialysis and Apheresis) and B.A.P. (BioArtProducts) intend to congregate partners from the Baltic Sea area for the future setup of a Baltic Apheresis Working Group, an initiative within the framework of the ScanBalt Flagship project "Baltic Sea Health Region" The initial aim of cooperation ('Memorandum of understanding" on a Baltic Apheresis Working Group) is to consolidate register and clinical case data on apheresis treatments from different Baltic Sea regions. This is also applicable for patients with a suggested indication for apheresis but not having access to this treatment. Today, apheresis technologies are very safe and can be used to treat a wide spectrum of metabolic, immunologic and rheologic disturbances. But despite numerous positive reports on apheresis therapy there is still no common understanding on how to properly evaluate its clinical effectiveness. There is an urgent need to improve awareness within the medical community on the special conditions of apheresis treatment and to develop new strategies how to properly design clinical trial protocols in particular disease entities. The federal state Mecklenburg-Vorpommern in the North of Germany is considered a leading region of apheresis treatment and research in Germany. A recently established collaboration within the Eco4Life project with partners from the department of nephrology of the Pomeranian Medical University, Szczecin, Poland, resulted in common activities in the scientific and educational field of apheresis treatment and the concept of a Baltic Apheresis Group (BAG).

### **Workshop Program**

Tuesday, 15th of October 2013

# From international experience to regional activities-workshop 1 09:00 - 10:45

chairs:Beate R. Jäger (Mühlheim-Ruhr), Wolfgang Ramlow(Rostock), L. Domanski (Szczecin)

 Selective apheresis technologies – from filtration to adsorption
 lörg Vienken, Apheresis Center Rostock (ACR), Germany

- Current status of lipoprotein apheresis in Saxonia, Ulrich Julius, *University of Dresden, Germany*
- Severe dyslipidemia in Italy the future role of apheresis therapy?
   Claudia Stefanutti, University La Sapienza, Rome, Italy
- Lipoprotein(a) apheresis in Germany results from a German multicenter apheresis trial Beate R. Jäger, Mühlheim-Ruhr, Germany

Coffee Break 10:45 - 11:15

# From international experience to regional activities - workshop 2

chairs: Wolfgang Ramlow (Rostock), Marek Myslak (Szczecin)

• First results from the German Lipoprotein Apheresis Registry

Volker Schettler, Beate R. Jäger, Christian Peter and Ulrich Julius, Germany

Proposal for an international lipoprotein apheresis database

Christian Peter, BAP, Wolfgang Ramlow, Apheresis Center Rostock, PDA, Rostock, Germany

- Polish criteria for apheresis treatment Future apheresis applications in Western Pomerania
   Marek Myslak, PUM, Szczecin, Poland
- Epidemiology of severe dyslipidemias in Western Pomerania Region Karolina Kedzierska, PUM, Szczecin, Poland

### **Ouick Lunch**

12:45 - 14:00

### **Apheresis for emerging indications**

ins 14:00 - 15:45

chairs: W. Szpirt (Copenhagen), S. Mitzner(Rostock)

- Immunoadsorption in dementia rationale and first results
   Rudolf Kunze, Berlin, Germany
- Plasma exchange in ANCA-associated renal vasculitis
   Wladimir Szpirt Rigshospitalet, Copenhagen, Denmark
- Apheresis treatment in dermatology
   Michael Jünger, Dermatological Hospital, University
   Medicine Greifswald, Germany
- Apheresis therapy a realistic treatment option in septic shock?
   Steffen Mitzner, University of Rostock, Germany

#### **Coffee Break**

15:45 - 16:15

Adsorptive cytapheresis in active ulcerative colitis – a chance for a collaborative ScanBalt approach for a randomized controlled apheresis trial

chairs: W. Ramlow(Rostock), L. Domanski (Szczecin)

- Current treatment options in ulcerative colitis Jörg Ringel, *PDA Rostock, Germany*
- Adsorptive cytapheresis in ulcerative colitis

   missed chances and future perspectives

   Heinrich Prophet, Apheresis Center Rostock, PDA, Germany
- Suggestions for a randomized controlled apheresis trial in patients with active ulcerative colitis in the ScanBalt region Grit Waitz, BAP Rostock, Germany

### **Memorandum of Understanding**

17:45

Signing MoU for Baltic Apheresis Working Group